Kwabena Owusu-Kyei

Kwabena Owusu-Kyei

Auto-generated profile, based on publicly available information

Kwabena Owusu-Kyei

Barcelona Catalonia Barcelona Institute for Global Health

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
DMDaniela Manno
Daniela Manno
CPCatriona Patterson
Catriona Patterson
ADAbdoulie Drammeh
Abdoulie Drammeh
KTKevin Tetteh
Kevin Tetteh
MKMattu Tehtor Kroma
Mattu Tehtor Kroma
DWDeborah Watson-Jones
Deborah Watson-Jones
We assessed whether the immunogenicity of the two-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen with a 56-day interval between doses was affected by exposure to malaria before dose 1 vaccination and by clinical episodes of malaria in the period immediately after dose 1 and after dose 2 vaccinations. Previous malaria exposure in participants in an Ebola vaccine trial in Sierra Leone (ClinicalTrials.gov: NCT02509494) was classified as low, intermediate, and high according to their antibody responses to a panel of Plasmodium falciparum antigens detected using a Luminex MAGPIX platform. Clinical malaria episodes after vaccinations were recorded as part of the trial safety monitoring. Binding antibody responses against the Ebola virus (EBOV) glycoprotein (GP) were measured 57 days post dose 1 and 21 days post dose 2 by ELISA and summarized as Geometric Mean Concentrations (GMCs). Geometric Mean Ratios (GMRs) were used to compare groups with different levels of exposure to malaria. Overall, 587 participants, comprising 188 (32%) adults (aged ≥ 18 years) and 399 (68%) children (aged 1–3, 4–11, and 12–17 years), were included in the analysis. There was no evidence that the anti-EBOV-GP antibody GMCs post dose 1 and post dose 2 differed between categories of previous malaria exposure. There was weak evidence that the GMC at 57 days post dose 1 was lower in participants who had had at least one episode of clinical malaria post dose 1 compared to participants with no diagnosed clinical malaria in the same period (GMR = 0.82, 95% CI: 0.69–0.98, p-value = 0.02). However, GMC post dose 2 was not reduced in participants who experienced clinical malaria post-dose 1 and/or post-dose 2 vaccinations. In conclusion, the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen is immunogenic in individuals with previous exposure to malaria and in those who experience clinical malaria after vaccination. This vaccine regimen is suitable for prophylaxis against Ebola virus disease in malaria-endemic regions.

27 September 2024 in Trials
Verified
Journal Article
Open access
PDF file
KOKwabena Owusu-Kyei
Kwabena Owusu-Kyei
HCHaily Chen
Haily Chen
MCMaureen Chileshe
Maureen Chileshe
LQLlorenç Quintó
Llorenç Quintó
MSMaya Sibley
Maya Sibley
ITIcaria Trial Team
Icaria Trial Team
Azithromycin has been shown to be beneficial in preventing infectious diseases, including malaria, infectious diarrhoea and pneumonia. A cluster randomised control trial on azithromycin MDA in children in Niger, Malawi and Tanzania found a reduction in all-cause under-five (U5) mortality in communities who received azithromycin compared to placebo. However, the reduction was largest and statistically significant only in Niger. The purpose of this trial is to evaluate the impact of azithromycin plus intermittent preventive treatment in infants (IPTi), recently renamed by the World Health Organisation as perennial malaria chemoprevention (PMC), with sulfadoxine-pyrimethamine (SP) on all-cause mortality up to 18 months of age in children living in areas of high mortality burden through the Expanded Program on Immunisation (EPI) in Sierra Leone. The Improving Care through Azithromycin Research for Infants in Africa (ICARIA) trial is a phase III two-arm, individually randomised, double-blinded, placebo-controlled trial administering oral AZI (20 mg/kg bodyweight) at three time points to children attending EPI visits in Sierra Leone. A total of 20,560 infants attending the first EPI contact at around 6 weeks of age are recruited and randomised to AZI or placebo in a 1:1 ratio. The second and third AZI/placebo doses are given at 9 and 15 months of age. The primary outcome of the trial is all-cause mortality rate at 18 months of age assessed through mortality surveillance. Other trial outcomes include the impact on antimicrobial resistance, and on the immune response to certain key routine EPI immunisations, the safety of the intervention, the prevalence of SP resistance markers and the feasibility, and acceptability of adding AZI to the EPI programme. The trial will provide the evidence needed to inform policy regarding the adoption and large-scale implementation of AZI in areas of high-mortality burden in sub-Saharan Africa. ClinicalTrials.gov NCT04235816. Registered on 22 January 2020. Pan-African Clinical Trials Registry PACTR202004540256535. Registered on 14 April 2020.

8 October 2025 in Gates Open Research
Verified
Journal Article
Open access
PDF file
HCHaily Chen
Haily Chen
KOKwabena Owusu-Kyei
Kwabena Owusu-Kyei
AFAugustin E. Fombah
Augustin E. Fombah
JWJulian Williams
Julian Williams
CGCarla García-Fernández
Carla García-Fernández
CMClara Menéndez
Clara Menéndez
Background Monitoring parasite resistance to antimalarial drugs is essential for detecting potential changes in drug efficacy. This study assessed the prevalence of molecular markers of resistance to sulfadoxine-pyrimethamine (SP), chloroquine, and artemisinin in Sierra Leone, where SP is used for intermittent preventive treatment in pregnancy (IPTp) and perennial malaria chemoprevention (PMC) in young children, while artemisinin is used to treat malaria episodes. Methods A cross-sectional survey was conducted between June and August 2021 in three districts of Sierra Leone. A total of 440 febrile children aged 2-5 years attending the health facilities were screened for P. falciparum malaria using a rapid diagnostic test, and 300 participants with positive RDT were enrolled. Capillary blood samples were collected as dried blood spots, analyzed using quantitative PCR to confirm P. falciparum, and sequenced for resistance markers in pfdhfr, pfdhps, pfcrt, pfmdr1, and pfK13. Results Of 298 blood samples, 237 (79.5%) were qPCR-positive and 230 samples were successfully genotyped. The pfdhfr triple mutant (N51I/C59R/S108N) was detected in 99.5% of samples (217/218), while pfdhps mutations A437G and K540E were detected in 92.1% (211/229) and 19.1% (42/220), respectively. The pfdhfr/dhps quintuple mutant (triple mutant + A437G/K540E) prevalence was 4.6% (7/151), and no sextuple mutants (quintuple + pfdhps -A581G) were observed. Chloroquine resistance-associated mutations in pfcrt (CVIET haplotype) were detected in 36.6% of samples, while pfmdr1 mutations at codon 86, 184, 1042, and 1246 occurred in 2.3%, 71.7%, 0.9% and 1.8%, respectively. No validated pfK13 markers of artemisinin resistance were detected. Conclusion In this study, the sustained low prevalence of pfdhfr/dhps quintuple mutant justifies the continued use of SP- containing IPTp and PMC, as well as its expansion in the country into the second year of life with additional SP doses. Importantly, no validated pfK13 markers were found supporting the use of artemisinin-based combination therapies in Sierra Leone. Trial registration Clinicaltrials.gov NCT04235816. Registered on January 17, 2020

26 January 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
KOKwabena Owusukyei
Kwabena Owusukyei
MBMaria Cussó Bordes
Maria Cussó Bordes
AFAugustin Eric Fombah
Augustin Eric Fombah
LQLlorenç Quintó
Llorenç Quintó
APAndreu Bofill Pumarola
Andreu Bofill Pumarola
CMClara Menéndez
Clara Menéndez
Background: Accurate data on morbidity and mortality among children under two years remain scarce in many low- and middle-income countries. We examined the causes and risk factors for severe morbidity and mortality among young children in Sierra Leone.Methods: We conducted a prospective cohort study nested within the ICARIA trial (NCT04235816), enrolling 20,560 infants aged 6–10 weeks between March 2021 and April 2024. The objective was to assess causes of hospital admission and death through 31 December 2024, when ~80% of children had completed 18-month follow-up. Hospital admissions, deaths, and immunisation status were captured through facility surveillance, household visits, phone follow-ups, and community informants. Causes of death were classified using ICD-10 and the WHO 2016 verbal autopsy tool (InSilicoVA). Incidence rates were expressed per 1,000 child-months. Morbidity was analysed using negative binomial regression; in-hospital and post-discharge mortality using Cox models and penalized logistic regression, reporting incidence rate ratios (IRRs), hazard ratios (HRs), and odds ratios (ORs).Findings: Median follow-up was 16·6 months. There were 2 688 hospital admissions (excluding readmissions and in-hospital deaths), yielding an incidence of 8·67 per 1 000 child-months. Malaria (54·3%), lower respiratory infections including pneumonia (16·7%), diarrhoeal disease (9·6%), undernutrition (7·4%), and sepsis (4·8%) were the leading causes of admission. Among in-hospital deaths (n=241), the leading causes were malaria (50·6%), lower respiratory infections (17·0%), sepsis (13·7%), undernutrition (7·1%), and diarrhoeal disease (3·7%). Among community deaths (n=425), malaria (24·2%), lower respiratory infections (17·9%), other infectious diseases (17·2%), and diarrhoeal disease (12·7%) predominated. Post-discharge mortality was 33·8 per 1 000 child-months. Undernutrition increased in-hospital mortality (adjusted OR 1·60, 95% CI 1·21–2·12). Full immunisation reduced overall (HR 0·65, 95% CI 0·55–0·76), in-hospital (OR 0·71, 95% CI 0·54–0·95), and post-discharge mortality (HR 0·56, 95% CI 0·33–0·92).Interpretation: This study shows that despite major investments and implementation efforts, mortality among infants and young children in Sierra Leone remains high and predominantly caused by preventable infections. These findings highlight the significant unfinished agenda in global health and the urgent need for more effective tools and strategies.

23 September 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
KOKwabena Owusukyei
Kwabena Owusukyei
LQLlorenç Quintó
Llorenç Quintó
AFAugustin Eric Fombah
Augustin Eric Fombah
JWJulian Williams
Julian Williams
MCMaureen N. Chileshe
Maureen N. Chileshe
CMClara Menéndez
Clara Menéndez
Background: Mass azithromycin administration for infants is recommended in high mortality settings. There is a need to assess the impact of integrating age-based azithromycin with other child survival strategies delivered through the Expanded Program on Immunisation (EPI).Methods: In this individually randomized, placebo-controlled trial in Sierra Leone, 20 560 infants were randomized to receive either azithromycin (20 mg/kg) or placebo during routine immunization visits at 6 weeks, 9 and 15 months of age. All participants received up to six doses of Perennial Malaria Chemoprevention (PMC) during immunization contacts. The primary outcome was all-cause mortality up to 18 months of age.Findings: There were 425 deaths in the azithromycin group and 463 in the placebo group (adjusted hazard ratio, 0·93; 95% confidence interval [CI], 0·82-1·06; p=0·30). Azithromycin was associated with lower mortality within 30 days after the first dose (adjusted hazard ratio, 0·49; 95% CI, 0·26 – 0·91; p=0·02), with similar size but non-significant effects after subsequent doses. Azithromycin was associated with an 18% lower hazard of mortality up to 18 months of age among children who died at home (60% of all deaths) (subdistribution hazard ratio, 0·82; 95% CI, 0·69 – 0·97; p=0·02). Over 70% of children received all three azithromycin or placebo doses. Adverse events were similar in the two groups. Receiving all PMC doses corresponding to age was independently associated with a 37% reduction in mortality (p<0·0001).Interpretation: Three doses of azithromycin administered over the first 15 months of life did not significantly reduce all-cause mortality at 18 months. However, the reduction in early mortality supports that alternative azithromycin schedules in early infancy warrant further evaluation. The survival benefits associated with PMC, together with high intervention coverage through EPI delivery, highlight the potential of integrated platforms to deliver multiple child-survival interventions at scale in high-mortality settings.

30 September 2024 in Research Square
Verified
Preprint
Open access
PDF file
KOKwabena Owusu-Kyei
Kwabena Owusu-Kyei
HCHaily Chen
Haily Chen
MCMaureen Chileshe
Maureen Chileshe
LQLlorenç Quintó
Llorenç Quintó
MSMaya Sibley
Maya Sibley
CMClara Menéndez
Clara Menéndez
Background: Azithromycin has been shown to be beneficial in preventing infectious diseases, including malaria, infectious diarrhoea and pneumonia. A cluster randomised control trial on azithromycin MDA in children in Niger, Malawi and Tanzania found a reduction in all-cause under-five (U5) mortality in communities who received azithromycin compared to placebo. However, the reduction was largest and statistically significant only in Niger. The purpose of this trial is to evaluate the impact of azithromycin plus intermittent preventive treatment in infants (IPTi), recently renamed by the World Health Organisation as perennial malaria chemoprevention (PMC), with sulfadoxine-pyrimethamine (SP) on all-cause mortality up to 18 months of age in children living in areas of high mortality burden through the Expanded Program on Immunisation (EPI) in Sierra Leone. Methods: The Improving Care through Azithromycin Research for Infants in Africa (ICARIA) trial is a phase III two-arm, individually randomised, double-blinded, placebo-controlled trial administering oral AZI (20mg/kg bodyweight) at three time points to children attending EPI visits in Sierra Leone. A total of 20,560 infants attending the first EPI contact at around 6 weeks of age are recruited and randomised to AZI or placebo in a 1:1 ratio. The second and third AZI/placebo doses are given at 9 and 15 months of age. The primary outcome of the trial is all-cause mortality rate at 18 months of age assessed through mortality surveillance. Other trial outcomes include the impact on antimicrobial resistance, and on the immune response to certain key routine EPI immunisations, the safety of the intervention, the prevalence of SP resistance markers and the feasibility, and acceptability of adding AZI to the EPI program. Discussion: The trial will provide the evidence needed to inform policy regarding the adoption and large-scale implementation of AZI in areas of high-mortality burden in sub-Saharan Africa. Trial registration: ClinicalTrials.gov NCT04235816 Registered on 22 January 2020 Pan-African Clinical Trials Registry, PACTR202004540256535. Registered on 14 April 2020